You are here: Industry Insights > Mallinckrodt

News List

Mallinckrodt and Terumo Blood and Cell Technologies Announce Positive Recommendations in Australia for Public Funding of UVADEX® (methoxsalen) for ECP Administration with the THERAKOS® CELLEX® Photoph prnasia
October 28, 2021
Mallinckrodt plc (OTCMKTS: MNKKQ), a global biopharmaceutical company, and Terumo Blood and Cell Technologies, a global leader in blood component, therapeutic apheresis and cellular technologies...
Mallinckrodt obtains FDA approval for StrataGraft to treat thermal burns pharmaceutical-business-review
June 17, 2021
Mallinckrodt has received the US Food and Drug Administration (FDA) approval for StrataGraft to treat thermal burns with intact dermal elements in adults.
Silence Therapeutics Gets Milestone Payment from Mallinckrodt Collaboration americanpharmaceuticalreview
April 30, 2021
Silence Therapeutics announced that it has achieved another research milestone as part of its ongoing RNAi collaboration with Mallinckrodt plc for complement-mediated diseases, triggering a further $2.0 million payment to Silence.
Mallinckrodt Receives Approval in Japan of the CELLEX® Extracorporeal Photopheresis System for Treatment of Chronic Graft Versus Host Disease PharmaSources.com
February 01, 2021
DUBLIN – January 27, 2021 – Mallinckrodt plc, a global biopharmaceutical company, announced today that Japan's Ministry of Health, Labour and Welfare (MHLW) approved the CELLEX® extracorporeal photopheresis (ECP) system.
Mallinckrodt launches retrospective study for inhaled therapy in COVID-19 pharmatimes
November 12, 2020
Mallinckrodt has launched a retrospective chart review study which will collect real-world data on the use of INOmax (nitric oxide) gas for inhalation therapy in patients with respiratory complications associated with COVID-19.
Mallinckrodt files for bankruptcy to resolve opioid claims pharmaceutical-technology
October 14, 2020
Mallinckrodt has initiated Chapter 11 proceedings in the US Bankruptcy Court for the District of Delaware to modify its capital structure, reduce debt and settle opioid claims.
US FDA denies approval to Mallinckrodt for Terlipressin to treat Hepatorenal Syndrome Type 1 expresspharma
September 16, 2020
The Complete Response Letter stated that, based on the available data, the agency cannot approve the terlipressin NDA in its current form and requires more information to support a positive risk-benefit profile for terlipressin for patients with HRS-1.
US committee backs terlipressin approval for HRS-1 pharmatimes
July 17, 2020
A US FDA advisory committee has voted in favour of approving Dublin, Ireland-based biopharma Mallinckrodt's terlipressin for Hepatorenal Syndrome Type 1 (HRS-1).
Mallinckrodt explores iNO as potential Covid-19 therapy pharmaceutical-technology
March 16, 2020
Mallinckrodt has started exploring inhaled nitric oxide (iNO) as a potential supportive measure for COVID-19 patients with pulmonary complications.
Mallinckrodt agrees to pay $1.6bn to settle opioid claims pharmaceutical-technology
March 04, 2020
Mallinckrodt has entered into a tentative agreement with 47 states, territories and lawyers in the US to pay $1.6bn to settle thousands of opioid-related lawsuits.

Previous page 1 2 3 4 5 Next page